These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20211915)

  • 21. [Interferon-beta in multiple sclerosis--who is going to be treated?].
    Aarli JA
    Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3114. PubMed ID: 10522472
    [No Abstract]   [Full Text] [Related]  

  • 22. Interferon beta in multiple sclerosis. Reducing frequency and severity of relapses will be of great clinical benefit.
    Burnfield A
    BMJ; 1997 Feb; 314(7080):600. PubMed ID: 9055727
    [No Abstract]   [Full Text] [Related]  

  • 23. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon beta: the current position.
    Boothman BR
    Br J Hosp Med; 1997 Mar 19-Apr 1; 57(6):277-80. PubMed ID: 9196574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of disseminated sclerosis with beta-inferferon--why and why not?].
    Sørensen PS; De Neergaard L
    Ugeskr Laeger; 1999 May; 161(19):2790. PubMed ID: 10412314
    [No Abstract]   [Full Text] [Related]  

  • 26. [Interferon beta-1b in multiple sclerosis--news regarding open questions].
    Nervenarzt; 1997 Aug; 68(8 Suppl Interferon):1-4. PubMed ID: 9380220
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment of multiple sclerosis with interferon beta 1b.
    Dhib-Jalbut S; McFarland HF
    Baillieres Clin Neurol; 1997 Oct; 6(3):467-80. PubMed ID: 10101584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon beta produces only small benefits in multiple sclerosis.
    McKee L
    BMJ; 1998 May; 316(7142):1410. PubMed ID: 9616008
    [No Abstract]   [Full Text] [Related]  

  • 30. [Pragmatic approach to treatments in multiple sclerosis].
    Vermersch P
    Rev Neurol (Paris); 2009 Apr; 165 Spec No 2():F125-31. PubMed ID: 19593885
    [No Abstract]   [Full Text] [Related]  

  • 31. Biogen wins Euro MS approval, but loses patents.
    Brower V
    Nat Biotechnol; 1997 May; 15(5):410. PubMed ID: 9131611
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment of multiple sclerosis with interferons].
    Nogales-Gaete J; Arriagada C
    Rev Med Chil; 1996 May; 124(5):597-604. PubMed ID: 9035514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Multiple sclerosis: therapy with recombinant beta-1b interferon: initial results with 30 multiple sclerosis patients in northwest Switzerland].
    Huber S; Spycher M; Lechner-Scott J; Bellaiche Y; Steck AJ; Kappos L
    Schweiz Med Wochenschr; 1996 Aug; 126(35):1475-81. PubMed ID: 8927950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New treatments for multiple sclerosis.
    Hutchinson M
    Ir Med J; 1996; 89(2):44. PubMed ID: 8682623
    [No Abstract]   [Full Text] [Related]  

  • 35. [Interferon beta-1b. New therapy for patients with secondary progressive multiple sclerosis].
    Nervenarzt; 1999 May; 70(5 Suppl):1-12. PubMed ID: 10368803
    [No Abstract]   [Full Text] [Related]  

  • 36. [Biosimilar: can we manage biopharmaceutical heterogeneity?].
    Ranieri E
    G Ital Nefrol; 2008; 25(3):275. PubMed ID: 18473296
    [No Abstract]   [Full Text] [Related]  

  • 37. Multiple sclerosis. Treatment is shifting.
    Mayo Clin Health Lett; 2003 Jan; 21(1):6. PubMed ID: 12619619
    [No Abstract]   [Full Text] [Related]  

  • 38. Early onset multiple sclerosis: more emphasis on early treatment.
    Minagar A
    Neuropediatrics; 2006 Aug; 37(4):207-8. PubMed ID: 17177146
    [No Abstract]   [Full Text] [Related]  

  • 39. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.
    Calabresi PA; Tranquill LR; Dambrosia JM; Stone LA; Maloni H; Bash CN; Frank JA; McFarland HF
    Ann Neurol; 1997 May; 41(5):669-74. PubMed ID: 9153530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment and management of neutralizing antibodies in patients with multiple sclerosis.
    Hartung HP; Munschauer FE
    J Neurol; 2004 Jun; 251 Suppl 2():II40-2. PubMed ID: 15264111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.